Author, year, country, sample size, and treatment type | Intervention description (type, setting, delivery) | Factors targeted | Intervention time point(s) by channel/technique | Significant outcomes on adherence and effect size | |||||
---|---|---|---|---|---|---|---|---|---|
Channel | Predischarge | 0–1 month | 1–3 months | 3–6 months | 6–12 months | ||||
Gujral, 2014, Australia n=200 (100 per group) Lipid-lowering agents ACE-I/ARB or β-blocker |
|
| Face-to-face community pharmacy adherence check and practical treatment discussion | X | X | X | X | No statistically significant outcomes on adherence as measured by prescription refill (MPR≥80%), or self-reported MARS at 6 and 12 months | |
Face-to-face community pharmacy counselling based on individual treatment beliefs uncovered by researchers | X | X | |||||||
Researcher interviews with patients to uncover individual treatment | X | X | X | ||||||
Khonsari, 2015, Malaysia n=62 (31 per group) Cardiac medications ‘in general’ |
|
| Daily SMS reminders | X | X | At 8 weeks postdischarge, 65% of participants in the intervention group had high self-reported adherence (MMAS-8=8) compared with 13% in the usual-care group (p<0.001) | |||
Prescription refill SMS reminders | X | ||||||||
Fortnightly telephone calls from research team to check receipt of SMS, check for emergency admissions and appointment attendance | X | X | |||||||
Muñiz, 2010, Spain n=1757 (867 intervention 890 control) Aspirin Clopidogrel β-blockers ACE-inhibitors ARA II Statins |
|
| 30-to-40 min hospital physician interview with patient and next of kin | X | X | No statistically significant outcomes on adherence as measured by self-reported persistence with treatment at 6 months. | |||
Signed agreement between physician and patient on therapeutic aims | X | ||||||||
Written educational materials (treatment, illness, secondary prevention) | X | X | |||||||
Inbound telephone support | X | X | X | ||||||
Palacio, 2015, USA n=422 (213 intervention 209 control) Antiplatelet therapy |
|
| 60 min quarterly motivational interviewing-based call conducted by nurse with patient | X | X | X | X | At 12 months postprocedure, 64% of patients in the MINT group had high adherence (MPR≥80) compared with 50% in video group (p≤0.001) Mean MPR in MINT group was 0.77 compared with 0.70 in video group (p≤0.005) | |
Treatment education video | X | ||||||||
Rinfret, 2013, Canada n=300 (150 per group) Clopidogrel |
|
| 5–10 min nurse calls to the patient to check adherence and reinforce need for treatment | X | X | X | X | 12-month persistence was 87.2% in the intervention group compared with 43.1% in the usual care group (p=<0.001) as measured by pharmacy prescription refill data. 12-month median adherence (number of pills/365 days) was 99.3% in the intervention group compared with 91.5% in the usual care group (p≤0.001) as measured by pharmacy prescription refill data. | |
Uysal, 2015, Turkey n=200 (100 per group) Aspirin Plavix ACE inhibitors β-blockers Calcium channel blockers Diuretics Statins |
|
| 60 min face-to-face education and counselling session | X | At 3 months postdischarge, intervention group had higher mean adherence (MMAS=1.4) compared with control group (MMAS=3.6) (p≤0.005). | ||||
5–10 min telephone education and counselling session | X | X |
MARS, Medication Adherence Report Scale; MMAS, Morisky Medication Adherence Scale; MPR, medication possession ration.